ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2018
The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Risk score model for predicting mortality among patients with lung cancer.Frontiers in medicine · 2024Article
- Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study.European urology open science · 2022Article
- Influence of border-age on survival of sporadic renal cell carcinoma: young adults versus octogenarians.International urology and nephrology · 2020Article
- Article
- Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes.Cancer medicine · 2019Article
- Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionContemporary data regarding the effect of age, especially in elderly patients, on cancer-specific mortality (CSM) for pT1a renal cell carcinoma (RCC) are lacking. The objective of the current study is to evaluate CSM in a large population-based cohort of surgically treated pT1a RCC patients according to age groups.
methodsWithin the Surveillance Epidemiology and End Results database (2000-2013), we identified 37 121 pT1a RCC patients who underwent either partial or radical nephrectomy. The population was stratified into five groups according to decades: <50, 50-59, 60-69, 70-79, and ≥80 years. The effect of age on CSM was evaluated using competing risks regression models according to Fuhrman grade (FG). Analyses were repeated in clear-cell RCC (ccRCC).
resultsPatients aged 50-59 (9615), 60-69 (10 762), 70-79 (7096), and ≥80 (1789) years demonstrated higher rate of CSM compared to patients aged <50 (7856) years (hazard ratios [HR] 2.11, 3.04, 4.47, and 7.56, respectively; all p<0.001). The effect of age on CSM in FG 1-2 patients resulted in HRs ranging from 2.01-8.23 for the same age decades (all p< 0.001). Similarly, the effect of age on CSM in FG 3-4 patients resulted in HRs ranging from 2.38-5.92, respectively (all p<0.001). Virtually the same results were recorded in ccRCC patients.
conclusionsOlder age is associated with higher CSM in surgically treated patients with pT1a RCC. This effect seems to be more pronounced in patient with FG 1-2 disease. This observation should be considered when making treatment decisions in elderly patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.